Soligenix, Inc. to Present at the virtual Fall Investor Summit on November 16th-18th
Soligenix, Inc. (NASDAQ:SNGX) will present at the virtual Fall Investor Summit from November 16-18, 2020. This summit features 75 companies and over 300 investors, providing a platform for small and micro-cap companies to connect with qualified investors. Soligenix focuses on developing treatments for rare diseases and includes products like SGX301 for cutaneous T-cell lymphoma and SGX942 for oral mucositis. The company also advances vaccine candidates targeting various infections, supported by government funding.
- None.
- None.
NEW YORK, NY / ACCESSWIRE / November 12, 2020 / Soligenix, Inc. (NASDAQ:SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, will be presenting at this year's virtual Fall Investor Summit on November 16th-18th.
The Fall Investor Summit will take place virtually, featuring 75 companies and over 300 institutional and retail investors.
About Soligenix, Inc.
Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Our Specialized BioTherapeutics business segment is developing SGX301 as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer, and proprietary formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation including pediatric Crohn's disease (SGX203) and acute radiation enteritis (SGX201).
Our Public Health Solutions business segment includes active development programs for RiVax®, our ricin toxin vaccine candidate, SGX943, our therapeutic candidate for antibiotic resistant and emerging infectious disease, and our research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19). The development of our vaccine programs incorporates the use of our proprietary heat stabilization platform technology, known as ThermoVax®. To date, this business segment has been supported with government grant and contract funding from the National Institute of Allergy and Infectious Diseases (NIAID), the Defense Threat Reduction Agents (DTRA) and the Biomedical Advanced Research and Development Authority (BARDA).
For further information regarding Soligenix, Inc., please visit the Company's website at www.soligenix.com.
The Investor Summit (formerly MicroCap Conference) is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.
To register as a presenting company: please contact Brittney Blocker (brittney@investorsummitgroup.com)
To request complimentary investor registration: please visit our website at www.investorsummitgroup.com
News Compliments of ACCESSWIRE
FOR MORE INFORMATION
Please visit: www.investorsummitgroup.com
Or, contact Brittney Blocker at brittney@investorsummitgroup.com
SOURCE: Soligenix, Inc.
View source version on accesswire.com:
https://www.accesswire.com/615982/Soligenix-Inc-to-Present-at-the-virtual-Fall-Investor-Summit-on-November-16th-18th
FAQ
When is Soligenix presenting at the Fall Investor Summit?
What is the focus of Soligenix's business?
What products is Soligenix developing?
How many companies are participating in the Fall Investor Summit?
What kind of investors will attend the Fall Investor Summit?
